Teva Invests $700 Million to Acquire Innovative Tourette Syndrome Treatment

Tel Aviv, Wednesday, 29 April 2026.
Teva is acquiring Emalex Biosciences for $700 million to secure Ecopipam, a pioneering late-stage treatment for pediatric Tourette syndrome, strategically positioning the company for long-term growth.